Research Paper
American Journal of Heart & Circulatory Physiology: Development and Characterization of a Mass Cytometry Panel for Detecting the Effect of Acute Doxorubicin Exposure on Murine Cardiac Non-myocytes (Bishop, Chen, & Aune Labs)
June 8, 2022
Brian S. Iskra, Logan R. Davis, Henry E. Miller, Yu-Chiao Chiu, Alexander J.R. Bishop, Yidong Chen, and Gregory J. Aune Abstract Childhood cancer survivors (CCSs) face lifelong side effects related to their treatment with chemotherapy. Anthracycline agents, such as doxorubicin (DOX), are important in the treatment of childhood cancers but are associated with cardiotoxicity. Cardiac toxicities represent a significant source [...]Molecular Cancer Therapeutics: Comprehensive Surfaceome Profiling to Identify and Validate Novel Cell-Surface Targets in Osteosarcoma (Houghton, Kurmasheva)
June 1, 2022
Yifei Wang; Xiangjun Tian; Wendong Zhang; Zhongting Zhang; Rossana Lazcano; Pooja Hingorani; Michael E. Roth; Jonathan D. Gill; Douglas J. Harrison; Zhaohui Xu; Sylvester Jusu; Sankaranarayanan Kannan; Jing Wang; Alexander J. Lazar; Eric J. Earley; Stephen W. Erickson; Tara Gelb; Philip Huxley; Johanna Lahdenranta; Gemma Mudd; Raushan T. Kurmasheva; Peter J. Houghton; Malcolm A. Smith; [...]Cancer Letters: The antidepressant imipramine inhibits breast cancer growth by targeting estrogen receptor signaling and DNA repair events (Rao & Chen Labs)
May 18, 2022
Santosh Timilsinaab1 Subapriya Rajamanickambc1 Arhan Raoh Panneerdoss Subbarayaluab Saif Nirzhorab Nourhan Abdelfattahi Suryavathi Viswanadhapallie Yidong Chenbd IsmailJatoif Andrew Brennerg Manjeet K.Raoab Ratna Vadlamudie Virginia Kaklamanig Highlights • Anti-depressant imipramine blocks the growth and progression of breast cancers. • Imipramine induces cell cycle arrest and blocks heightened DNA repair activities in breast cancer cells. • Imipramine [...]JCO Oncology Practice: Disparities in Cancer Genetic Testing and Variants of Uncertain Significance in the Hispanic Population of South Texas (Tomlinson Lab, Ignatius Lab)
May 12, 2022
Stephanie Soewito, BS, MS1; Rachel Wyatt, MS2; Emily Berenson, MS2; Natalie Poullard, MS, MA3; Shawn Gessay, MS2,3,4; Lindsey Mette, MS, MPH2,3,5; Elena Marin, CHW6; Kristin Shelby, BA6; Elise Alvarez, BA3; Byeong Yeob Choi, PhD7; Clarissa Aviles, MSHS6; Anna Maria Pulido-Saldivar, MPH6,8; Pamela M. Otto, MD9; Ismail Jatoi, MD3,10; Chethan Ramamurthy, MD3; Myron Ignatius, PhD6; Virginia G. Kaklamani, MD, DSc3; and Gail E. Tomlinson, MD, PhD2,3,6 PURPOSE: Racial and ethnic disparities have included [...]Molecular Carcinogenesis: SIRT1 inhibition-induced senescence as a strategy to prevent prostate cancer progression (Chen, Lai)
April 25, 2022
Abstract Emerging evidence suggests an important role for SIRT1, a nicotinamide adenine dinucleotide (NAD)-dependent deacetylase in cancer development, progression, and therapeutic resistance; making it a viable therapeutic target. Here, we examined the impact of resveratrol-mediated pharmacological activation of SIRT1 on the progression of HGPIN lesions (using the Pten−/− mouse model) and on prostate tumor development (using [...]Oncogene: Targeting farnesylation as a novel therapeutic approach in HRAS-mutant rhabdomyosarcoma (Vaseva)
April 25, 2022
Patience Odeniyide, Marielle E. Yohe, Kai Pollard, Angelina V. Vaseva, Ana Calizo, Lindy Zhang, Fausto J. Rodriguez, John M. Gross, Amy N. Allen, Xiaolin Wan, Romel Somwar, Karisa C. Schreck, Linda Kessler, Jiawan Wang & Christine A. Pratilas Abstract Activating RAS mutations are found in a subset of fusion-negative rhabdomyosarcoma (RMS), and therapeutic strategies to directly [...]Clinical Cancer Research: The B7-H3-Targeting Antibody-Drug Conjugate m276-SL-PBD Is Potently Effective Against Pediatric Cancer Preclinical Solid Tumor Models (Kurmasheva & Houghton)
April 22, 2022
Nathan M Kendsersky # 1 2, Jarrett Lindsay # 1 2, E Anders Kolb 3, Malcolm A Smith 4, Beverly A Teicher 4, Stephen W Erickson 5, Eric J Earley 5, Yael P Mosse 1, Daniel Martinez 6, Jennifer Pogoriler 2 6, Kateryna Krytska 1, Khushbu Patel 1 7, David Groff 1, Matthew Tsang 1, Samson Ghilu 8, Yifei Wang 9, Steven Seaman 10, Yang Feng 10, Brad St Croix 10, Richard Gorlick 9, Raushan Kurmasheva 8, Peter J Houghton 11, John M Maris 12 2 Abstract Purpose: Patients with relapsed pediatric solid malignancies have few therapeutic options, and many of these patients die of their disease. B7-H3 [...]Non-Coding RNA: Current Status of Epitranscriptomic Marks Affecting lncRNA Structures and Functions (Bishop Lab)
April 22, 2022
by Henry E. Miller 1,2,3ORCID, Mirolyuba Ilieva 4, Alexander J. R. Bishop 1,2,5ORCID and Shizuka Uchida 4, Non-Coding RNA 2022, 8(2), 23; https://doi.org/10.3390/ncrna8020023 Received: 1 March 2022 / Revised: 21 March 2022 / Accepted: 25 March 2022 / Published: 28 March 2022 Abstract Long non-coding RNAs (lncRNAs) belong to a class of non-protein-coding RNAs with [...]BMC: SETDB1 interactions with PELP1 contributes to breast cancer endocrine therapy resistance (Lai, Chen, Rao)
April 11, 2022
Zexuan Liu, Junhao Liu, Behnam Ebrahimi, Uday P. Pratap, Yi He, Kristin A. Altwegg, Weiwei Tang, Xiaonan Li, Zhao Lai, Yidong Chen, Liangfang Shen, Gangadhara R. Sareddy, Suryavathi Viswanadhapalli, Rajeshwar R. Tekmal, Manjeet K. Rao & Ratna K. Vadlamudi Abstract Background Methyltransferase SETDB1 is highly expressed in breast cancer (BC), however, the mechanisms by which SETDB1 [...]Cancer Research: M6A RNA Methylation Regulates Histone Ubiquitination to Support Cancer Growth and Progression (Gupta, Zheng, Houghton, Chen, and Rao Labs)
March 21, 2022
Pooja Yadav; Panneerdoss Subbarayalu; Daisy Medina, Saif Nirzhor; Santosh Timilsina; Subapriya Rajamanickam; Vijay K. Eedunuri; Yogesh Gupta Siyuan Zheng Nourhan Abdelfattah Yufei Huang Ratna Vadlamudi Robert Hromas; Paul Meltzer Peter Houghton; Yidong Chen Manjeet K. Rao Abstract Osteosarcoma is the most common malignancy of the bone, yet the survival for osteosarcoma patients is virtually unchanged [...]